Adagrasib

GSK is handing over $110 million upfront to Hutchmed in a deal worth up to $1.295 billion to get its hands on a first-in-class oncology med. That asset is HMPL-A830, a preclinical KRAS-EGFR-antibody conjugate that is slated to enter trials later this year. The deal gives the British Big Pharma worldwide rights to develop and sell the therapy—but excludes Mainland China, Hong Kong, Macau and Taiwan. HMPL-A830 works by delivering a KRAS inhibitor directly to EGFR-expressing tumors. At the same, it also blocks EGFR and KRAS signaling to “enhance efficacy, durability, and tolerability,” the companies said in a release . Clinical development of the asset will initially revolve around colorectal, pancreatic and lung cancer indications, with the pair noting that those malignancies "have the highest incidence of patients with KRAS-altered tumors.” Under the deal, Hutchmed will work on Phase 1 trials, with GSK then taking over all R&D responsibilities and commercialization outside of select territories in Asia. “This agreement reflects GSK’s growing leadership across oncology and our commitment to advance the latest innovation for patients living with cancer,” said Hesham Abdullah, M.D., Senior Vice President, Global Head Oncology, R&D, GSK, in the release. “The dual KRAS-EGFR mechanism of HMPL-A830 has the potential to significantly improve upon current standard of care," he added. KRAS was once deemed an undruggable target, but wins have started to crop up in the space over the past few years. The biggest was for Bristol Myers Squibb’s Krazati, which has gained accelerated FDA approvals in non-small cell lung cancer and colorectal cancer. Whether BMS can turn that latter accelerated nod into a full approval is in now question though, after a confirmatory trial failed to meet its survival goals earlier this summer. EGFR-expressing tumors are more often found in certain NSCLC, head and neck and brain tumors. Specific drugs for these mutations include older medicines such as AstraZeneca’s Tagrisso and Iressa, plus Cheplapharm’s (formerly Roche’s) Tarceva.

GSK’s deal with HUTCHMED marks the latest in a long line of licensing activities between Western pharma companies and Chinese drug developers. Credit: testing/Shutterstock.com. GSK will pay a subsidiary of HUTCHMED $110m upfront for a novel type of drug designed to selectively target solid tumours. Under the licensing deal, a subsidiary of GSK will gain global rights to the cancer candidate HMPL-A830, although HUTCHMED will retain development and commercialisation activities in Mainland China, Hong Kong, Macau and Taiwan. China-based HUTCHMED is also in line for development, regulatory and commercial milestone payments worth $1.185bn, meaning the deal could reach a total value of $1.295bn. HMPL-A830 is an antibody-targeted therapy conjugate (ATTC), comprising of a Kirsten rat sarcoma (KRAS) small molecule inhibitor payload joined to an anti-epidermal growth factor receptor (EGFR) antibody. According to HUTCHMED, ATTCs mark an advancement on traditional cytotoxin-based antibody-drug conjugates (ADCs), allowing strong anti-tumour activity while maintaining durability. HMPL-A830 is designed to deliver a KRAS inhibitor directly to EGFR-expressing tumours, while simultaneously blocking EGFR and KRAS signalling to enhance efficacy, durability, and tolerability. GSK’s global head of oncology R&D, Dr Hesham Abdullah, said: “The dual KRAS-EGFR mechanism of HMPL-A830 has the potential to significantly improve upon current standard of care.” KRAS is a specific type of gene and protein belonging to the broader RAS family, which acts as a cellular switch for growth and division. Mutations across the entire RAS family drive roughly 15% to 20% of all human cancers, meaning the protein has become one of the most prevalent drivers in human oncology. KRAS, the most dominant RAS isoform, is mutated in approximately 44% of colorectal cancer, 34% of lung adenocarcinoma and up to 89% of pancreatic ductal adenocarcinoma patients. Because of this, HUTCHMED said that clinical development with HMPL-A830 will initially focus on these three cancer indications. The top-selling KRAS inhibitor is Amgen’s Lumakras/Lumykras (sotorasib), which reached sales of $363m in 2025. Bristol Myers Squibb’s (BMS) Krazati (adagrasib) is also emerging as a widely used therapy, with sales growing 62% to $205m in 2025. HUTCHMED plans to initiate a global Phase I development programme (NCT07718581) in the second half of 2026, which it will still be responsible for as part of the deal terms with GSK. The study will feature both a dose escalation part and a dose optimisation portion, with enrolled patients having confirmed, unresectable, advanced, or metastatic solid tumours who are refractory or not responding to standard treatment. HMPL-A830 is HUTCHMED’s third candidate using this payload framework. HMPL-A251, a PI3K/PIKK–HER2 ATTC, and HMPL-A580, a PI3K/PIKK–EGFR ATTC, are both in clinical trials. HMPL-A830, however, marks the first licensed to a global partner. For GSK, licensing HMPL-A830 aligns with a new R&D strategy debuted by recently appointed CEO Luke Miels in July 2026. In its Q2 earnings, the company announced it would save $2.5bn between now and 2029, most of which will be reallocated to bolstering its pipeline through dealmaking, regular portfolio reviews and the acceleration of late-stage R&D programmes. GSK’s deal with HUTCHMED marks the latest in a long line of licensing activities between Western pharma companies and Chinese drug developers. An October 2025 report from GlobalData, parent company of Pharmaceutical Technology , found that China-based companies were responsible for 20% of drugs in development globally , reflecting the powerhouse role the country has embraced in the pharmaceutical industry. Cross-border licensing hit $136bn in 2025 – a value more than 27 times higher than the $5bn rate seen in 2020.